Trial Profile
A Phase 1, 2-Part, Open-Label, Single-Dose, Parallel Group Study to Determine the Effect of Hepatic Impairment on the Safety, Tolerability, and Pharmacokinetics of ACH-0144471 in Adult Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Danicopan (Primary)
- Indications COVID 2019 infections; Dry age-related macular degeneration; Paroxysmal nocturnal haemoglobinuria
- Focus Pharmacokinetics
- Sponsors Achillion Pharmaceuticals; Alexion Pharmaceuticals
- 08 Jan 2019 Status changed from recruiting to completed.
- 19 Jun 2018 New trial record